Sexually transmitted infections in Spain: Current status.

Gonococcal infections HIV Herpes simplex virus High risk groups Human Papillomavirus Monkeypox Mycoplasma genitalium Neisseria gonorrhoeae Public Health STD STI Sexually Transmitted Diseases Sexually Transmitted Infections syphilis

Journal

Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia
ISSN: 1988-9518
Titre abrégé: Rev Esp Quimioter
Pays: Spain
ID NLM: 9108821

Informations de publication

Date de publication:
Oct 2023
Historique:
medline: 25 9 2023
pubmed: 19 6 2023
entrez: 19 6 2023
Statut: ppublish

Résumé

Sexually Transmitted Infections (STI) are a major public health problem. The problems inherent to their diagnosis, treatment and prevention have to do not only with their nature, but also with organizational issues and overlapping competencies of the different health authorities in Spain. The real situation of STI in Spain, at present, is poorly known. For this reason, the Scientific Committee on COVID and Emerging Pathogens of the Illustrious Official College of Physicians of Madrid (ICOMEM) has formulated a series of questions on this subject which were distributed, not only among the members of the Committee, but also among experts outside it. The central health authorities provide very high and increasing figures for gonococcal infection, syphilis, Chlamydia trachomatis infection and lymphogranuloma venereum (LGV). Both HIV infection and Monkeypox are two important STI caused by viruses in our environment, to which it should be added, mainly, Herpes simplex virus (HSV) and Human papillomavirus (HPV) infections. Emerging microorganisms such as Mycoplasma genitalium pose not only pathogenic challenges but also therapeutic problems, as in the case of N. gonohrroeae. The pathways that patients with suspected STI follow until they are adequately diagnosed and treated are not well known in Spain. Experts understand that this problem is fundamentally managed in public health institutions, and that Primary Care and Hospital Emergency Services, together with some institutions that deal monographically with this problem, are the recipients of most of these patients. One of the most serious difficulties of STI lies in the availability of the microbiological tests necessary for their diagnosis, particularly in this era of outsourcing of microbiology services. Added to this is the increased cost of implementing the latest generation of molecular techniques and the difficulties of transporting samples. It is clear that STI are not diseases to which the entire population is equally exposed and it is necessary to have a better knowledge of the risk groups where to focus the necessary interventions adapted to their characteristics. It should not be forgotten that STI are also a problem in the pediatric age group and that their presence can be a marker of sexual abuse with all that this implies in terms of health care and medicolegal activity. Finally, STI are infections that are associated with a high cost of care for which we have very little information. The possibility of expanding the automatic performance of laboratory tests for STI surveillance through laboratory routines is encountering ethical and legal problems that are not always easy to solve. Spain has created a ministerial area of specific attention to STI and there are plans to improve the diagnosis, treatment and prevention of these problems, but we still lack the necessary evidence on their impact. We cannot forget that these are diseases that transcend the individual and constitute a Public Health problem.

Identifiants

pubmed: 37335757
doi: 10.37201/req/038.2023
pmc: PMC10586737
pii:
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

444-465

Informations de copyright

©The Author 2023. Published by Sociedad Española de Quimioterapia. This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0)(https://creativecommons.org/licenses/by-nc/4.0/).

Références

Emergencias. 2022 Jun;34(3):204-212
pubmed: 35736525
IARC Monogr Eval Carcinog Risks Hum. 2007;90:1-636
pubmed: 18354839
MMWR Recomm Rep. 2021 Jul 23;70(4):1-187
pubmed: 34292926
J Antimicrob Chemother. 2021 May 12;76(6):1523-1531
pubmed: 33569588
J Infect. 2022 Oct;85(4):412-417
pubmed: 35830908
Rev Esp Quimioter. 2021 Aug;34(4):353-364
pubmed: 34060776
Clin Infect Dis. 2016 Nov 15;63(10):1281-1287
pubmed: 27655996
Clin Infect Dis. 2015 Nov 15;61(10):1601-3
pubmed: 26334052
JAMA. 2019 Jun 11;321(22):2214-2230
pubmed: 31184746
Acta Derm Venereol. 2010 Sep;90(5):461-7
pubmed: 20814619
Actas Dermosifiliogr. 2022 Feb;113(2):115-122
pubmed: 34538874
PLoS One. 2020 Mar 16;15(3):e0228998
pubmed: 32176884
Diagnostics (Basel). 2022 Jul 25;12(8):
pubmed: 35892506
Lancet Infect Dis. 2022 May;22(5):706-717
pubmed: 35065063
AIDS. 2015 Apr 24;29(7):819-24
pubmed: 25985403
J Sex Res. 2019 Nov-Dec;56(9):1128-1135
pubmed: 30777781
PLoS One. 2015 Jan 21;10(1):e114989
pubmed: 25608026
Lancet. 1981 Jun 13;1(8233):1288-91
pubmed: 6112607
Cancer Cytopathol. 2011 Feb 25;119(1):5-19
pubmed: 21319310
Clin Microbiol Rev. 2011 Jul;24(3):498-514
pubmed: 21734246
Emergencias. 2020 Nov;32(6):416-426
pubmed: 33275363
Int J STD AIDS. 2020 Oct 29;:956462420949126
pubmed: 33121366
Pediatrics. 2021 Jul;148(1):
pubmed: 34183359
Lancet. 2020 Jul 25;396(10246):239-254
pubmed: 32711800
JMIR Serious Games. 2022 Feb 2;10(1):e30526
pubmed: 35107438
Int J STD AIDS. 2020 Jan;31(1):4-15
pubmed: 31870237
PLoS One. 2021 Feb 4;16(2):e0245925
pubmed: 33539363
Antimicrob Agents Chemother. 2022 May 17;66(5):e0010922
pubmed: 35491832
Ann Intern Med. 2020 Dec 1;173(11):888-894
pubmed: 32956600
Emerg Infect Dis. 2018 Feb;24(2):328-335
pubmed: 29350154
Emergencias. 2021 Feb;33(1):7-8
pubmed: 33496393
J Eur Acad Dermatol Venereol. 2022 May;36(5):641-650
pubmed: 35182080
Enferm Infecc Microbiol Clin. 2005 Oct;23(8):482-4
pubmed: 16185563
Clin Infect Dis. 2019 Feb 1;68(4):554-560
pubmed: 29873691
Sex Transm Infect. 2018 Feb;94(1):14-20
pubmed: 28717050
Lancet Infect Dis. 2020 Nov;20(11):1302-1314
pubmed: 32622378
Enferm Infecc Microbiol Clin (Engl Ed). 2019 Aug - Sep;37(7):458-466
pubmed: 30732970
Bull World Health Organ. 2020 May 01;98(5):315-329
pubmed: 32514197
Sex Transm Infect. 2022 May 10;:
pubmed: 35537800
Arch Pathol Lab Med. 2020 Nov 1;144(11):1344-1351
pubmed: 32810868
Prev Med. 2017 Jul;100:143-144
pubmed: 28455221
Int J STD AIDS. 2020 Mar;31(3):190-197
pubmed: 32000587
Emergencias. 2021 Aug;33(4):254-264
pubmed: 34251138
Lancet Microbe. 2022 Apr;3(4):e303-e315
pubmed: 35544067
JAMA. 2019 Jun 11;321(22):2203-2213
pubmed: 31184747
JAMA. 2022 Jan 11;327(2):161-172
pubmed: 35015033
Lancet. 2013 Jun 15;381(9883):2083-90
pubmed: 23769234
J Infect Dis. 2022 Jun 1;225(11):2043-2049
pubmed: 34919679
Antimicrob Agents Chemother. 1992 Apr;36(4):870-2
pubmed: 1503451
J Infect Dis. 2017 Jan 15;215(2):202-208
pubmed: 27815379
Cochrane Database Syst Rev. 2014 Aug 03;(8):CD009036
pubmed: 25086573
J Clin Microbiol. 2007 Mar;45(3):847-50
pubmed: 17251394
Emergencias. 2021 Aug;33(4):249-250
pubmed: 34251136
J Infect Dis. 2016 Dec 15;214(12):1800-1807
pubmed: 27418048
Antibiotics (Basel). 2022 Feb 23;11(3):
pubmed: 35326763
Expert Rev Mol Diagn. 2022 Jan;22(1):29-48
pubmed: 34872437
Ther Adv Infect Dis. 2020 Oct 21;7:2049936120960664
pubmed: 33598210
Clin Infect Dis. 2015 Apr 15;60(8):1228-36
pubmed: 25537875
Euro Surveill. 2022 Jul;27(28):
pubmed: 35837964
JAMA Netw Open. 2020 Dec 1;3(12):e2030806
pubmed: 33355675
Lancet Microbe. 2021 Nov;2(11):e627-e636
pubmed: 35544082
Sex Transm Dis. 2022 Aug 1;49(8):e87-e89
pubmed: 35067599
JAMA. 2019 Apr 9;321(14):1380-1390
pubmed: 30964528
Antibiotics (Basel). 2022 Nov 16;11(11):
pubmed: 36421278
BMJ Open. 2022 Dec 1;12(12):e064934
pubmed: 36456026
J Infect Dis. 2022 Dec 13;226(12):2192-2203
pubmed: 36201640

Auteurs

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH